Corinne Veyret

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés et al. · The Lancet Oncology · 2014 · 146 citations

Medicine, Oncology, Pharmacotherapy +17

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy

François‐Clément Bidard, Claire Mathiot, Armelle Degeorges et al. · Annals of Oncology · 2010 · 143 citations · Full text

Medicine, Cancer Biology, Oncology +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment

Marie Lange, Natacha Heutte, Olivier Rigal et al. · The Oncologist · 2016 · 120 citations · Full text

Medicine, Geriatric Medicine, Oncology +17